Areas of Focus
- Epigenetic Innovative Drug Research
- Medicinal Chemistry
- C-H Activation Methodology
Work Experience
- 2016-03 to Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
- 2013-04 to 2016-03 - University of Michigan, USA - Postdoctoral Researcher
- 2011-06 to 2013-03 - Purdue University, USA - Postdoctoral Researcher
- 2007-04 to 2008-08 - Hutchison MediPharma (Shanghai) Ltd. - Associate Researcher
Academic Background & Achievements
- 2008-09 to 2011-06 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- 2004-09 to 2007-03 Master's: Tongji University
- 2000-09 to 2004-07 Bachelor's: Tongji University
Publications
- Cyclization strategy leads to highly potent Bromodomain and extra-terminal (BET) Bromodomain inhibitors for the treatment of acute liver injury, Bing Zhou, 2023
- Discovery of Highly Potent and Selective Thyroid Hormone Receptor Agonists for the Treatment of Nonalcoholic Steatohepatitis, Bing Zhou, 2023
- Discovery of a Potent and Selective Degrader for USP7, Bing Zhou, 2022
- The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma, Bing Zhou, 2022
- Rh(III)-catalyzed twofold unsymmetrical C-H alkenylation-annulation/amidation reaction enabled delivery of diverse furoquinazolinones, Bing Zhou, 2022
- Discovery of novel Thieno2,3-dimidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration, Bing Zhou, 2022
- Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors, Bing Zhou, 2022
- Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1), Bing Zhou, 2022
- Potent and Selective RIPK1 Inhibitors Targeting Dual-Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis, Bing Zhou, 2022
- A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1 and IL-6, Bing Zhou, 2022
- Rhodium(III)-Catalyzed Asymmetric 1,2-Carboamidation of Alkenes Enables Access to Chiral 2,3-Dihydro-3-benzofuranmethanamides, Bing Zhou, 2022
- The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma, Bing Zhou, 2022
- Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer, Bing Zhou, 2021
- Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3, Bing Zhou, 2021
- Rhodium-Catalyzed Twofold Unsymmetrical C-H Alkenylation-Annulation/Thiolation Reaction To Access Thiobenzofurans, Bing Zhou, 2021
- P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K delta inhibitor idelalisib, Bing Zhou, 2021
- Rh(III)-catalyzed selective C7-H functionalization of indolines with 1,3-enynes enables access to six-membered 1,7-fused indolines, Bing Zhou, 2021
- Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders, Bing Zhou, 2021
- Inhibition of autophagy by a small molecule through covalent modification of LC3 Protein, Bing Zhou, 2021
- Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors, Bing Zhou, 2021
- Rh(III)-catalyzed tandem annulative redox-neutral arylation/amidation of aromatic tethered alkenes, Bing Zhou, 2020
- Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain, Bing Zhou, 2020
- Ruthenium(II)-Catalyzed Regioselective C-H Hydroxymethylation of N-Aryl-azaindoles with Paraformaldehyde, Bing Zhou, 2020
- Ruthenium(II)-Catalyzed Regioselective Ortho C-H Allenylation of Electron-Rich Aniline and Phenol Derivatives, Bing Zhou, 2020
- Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion, Bing Zhou, 2020
- Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors, Bing Zhou, 2020
- BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma, Bing Zhou, 2020
- Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors, Bing Zhou, 2020
- Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-terminal (BET) Bromodomain Inhibitors, Bing Zhou, 2020
- Reduced asymmetric dimethylarginine accumulation through inhibition of the type I protein arginine methyltransferases promotes renal fibrosis in obstructed kidneys, Bing Zhou, 2019
- p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization, Bing Zhou, 2019
- Ru(II)-catalyzed regioselective C-7 hydroxymethylation of indolines with formaldehyde, Bing Zhou, 2019
- Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors, Bing Zhou, 2019
- Rh(III)-catalyzed Redox-Neutral Unsymmetrical C-H Alkylation and Amidation Reactions of N-Phenoxyacetamides, Bing Zhou, 2018
- Rh(III)-Catalyzed C-H Functionalization of Indoles with Diazo Compounds: Facile Synthesis of Structurally Diverse 2,3-Fused Indoles, Bing Zhou, 2018
- Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor, Bing Zhou, 2018
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression, Bing Zhou
Awards
- Shandong Province 'Outstanding Youth' (2024): Provincial Level
- Pudong New Area 'Mingzhu Elite Talent' (2023): Other
- Shandong Province Taishan Scholar Young Expert (2023): Provincial Level
- Shanghai Outstanding Young Academic Leader (2022): Provincial Level
- Shanghai Youth Science and Technology Star (2017): Provincial Level
- National High-Level Talent Introduction Youth Talent (2017): National Level
- Shanghai Pharmaceutical Science and Technology Award, Second Prize (2012): Provincial Level
